Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Dose, Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Determine the Abuse Potential of Single Oral Dose of Seltorexant Compared To Suvorexant and Zolpidem

NCT05106153 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT05106153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05106153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Dose, Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Determine the Abuse Potential of Single Oral Dose of Seltorexant Compared To Suvorexant and Zolpidem
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 1
Overall status
Completed
Start date
December 17, 2021
Completion date
May 12, 2023
Enrollment
127 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abuse potential, healthy non-dependent, recreational sedative users